0001722964
false
0001722964
2023-08-10
2023-08-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date of report (Date of earliest event
reported): August 10, 2023
Y-MABS THERAPEUTICS, INC.
(Exact name of registrant as specified
in its charter)
Delaware |
|
001-38650 |
|
47-4619612 |
(State or other jurisdiction of
incorporation or organization) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
230 Park Avenue
Suite 3350
New York, New York 10169
(Address of principal executive offices)
(Zip Code)
(646) 885-8505
(Registrant’s telephone number,
include area code)
N/A
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class: |
|
Trading Symbol |
|
Name of each exchange on which
registered: |
Common Stock, $0.0001 par value |
|
YMAB |
|
NASDAQ Global Select Market |
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial
Condition.
On August 10, 2023, Y-mAbs Therapeutics, Inc.,
announced its financial results for the quarter ended June 30, 2023. A copy of the press release is attached hereto as Exhibit 99.1.
The
information furnished pursuant to Item 2.02 on this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act or
the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
Y-MABS THERAPEUTICS, INC. |
|
|
|
Date: August 10, 2023 |
By: |
/s/ Thomas Gad |
|
|
Thomas Gad |
|
|
Founder, President, Interim Chief Executive Officer and Head of Business Development & Strategy |
Exhibit 99.1
Y-mAbs
Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
| · | Q2
2023 DANYELZA® record net product revenues of $20.8 million, driving YoY growth of 112%
and a 3% sequential increase compared to Q1 2023 |
| · | Management
reiterates FY 2023 financial guidance |
| · | DANYELZA
marketing authorization granted in Brazil |
| · | Ongoing
patient recruitment in the Phase I GD2-SADA trial |
| · | Cash
and cash equivalents of $87.9 million as of June 30, 2023, anticipated cash runway into
2026 |
| · | The
Company will host a conference call on Friday, August 11, 2023, at 9:00 a.m. EDT |
New
York, NY, August 10, 2023 (GLOBE NEWSWIRE) – Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)
(Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based
therapeutic products for the treatment of cancer, today reported financial results for the second
quarter of 2023.
"The second quarter of 2023 marked
another period of progress for DANYELZA with continued revenue growth and international expansion with regulatory approval in Brazil,”
said Thomas Gad, Founder, President, and Interim Chief Executive Officer. “As we continue patient enrollment in the Phase I GD2-SADA
study, we are pleased to report that we have closed Cohort 1 and Cohort 2 and are now dosing Cohort 3, and we have administered a 200
mCi dose of 177Lu-DOTA and an interval between dosing of the protein and the payload of between two to five days. We look forward to
presenting pk and imaging data from this study later this year at our R&D Day. Upon completion of our reorganization, we estimate
our existing cash and cash equivalents to support our business operations as currently planned into 2026, positioning us well to deliver
our therapies to more patients both in the U.S. and worldwide.”
Second
Quarter 2023 and Recent Corporate Developments
| · | On
July 2, 2023, the Company’s partner in China, SciClone Pharmaceuticals, announced
that they had officially launched DANYELZA. |
| · | On
May 26, 2023, Y-mAbs announced interim clinical data from study 201 with naxitamab in
combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”)
in patients with relapsed or refractory high-risk neuroblastoma and presented such interim
clinical data at the American Society of Clinical Oncology (“ASCO”) Annual Meeting
on June 2-6, 2023. |
| · | Also
at ASCO, Y-mAbs presented the design of its Phase I clinical study evaluating the Company’s
Self-Assembly DisAssembly Pre-targeted Radioimmunotherapy (“SADA Y-PRIT”) Theranostic
Platform for the treatment of certain GD2-positive solid tumors, including small cell lung
cancer, sarcoma, and malignant melanoma. |
| · | On
May 23, 2023, Y-mAbs announced that the Brazilian Health Regulatory Agency, Agência
Nacional de Vigilância Sanitária (“ANVISA”) granted marketing authorization
for DANYELZA (naxitamab-gqgk). |
| · | On
April 18, 2023, Y-mAbs announced that positive preclinical data had been presented on
naxitamab in triple-negative breast cancer at the American Association for Cancer Research
(“AACR”) Annual Meeting. |
| · | On
April 5, 2023, Y-mAbs announced that the first patient had been dosed in the Phase I
clinical study evaluating the Company’s SADA Y-PRIT Theranostic Platform for the treatment
of certain GD2-positive solid tumors. |
Financial Results
Revenues
Y-mAbs reported DANYELZA net product
revenues of $20.8 million and $41.0 million
for the quarter and six months ended June 30, 2023, which represented increases of 112%
and 102%, respectively, over $9.8 million and $20.3 million in the comparable periods of
2022.
The DANYELZA net product revenues for
the quarter ended June 30, 2023 represents an increase of 3% compared to the first
quarter of 2023. The $0.5 million sequential increase was driven by international revenues
and related royalties, which included $3.5 million of revenues and related royalties for the China commercial launch inventory stocking
order from SciClone, which Y-mAbs does not anticipate recurring at this level each quarter. This increase was partly offset by a softening
in new U.S. patients in the second quarter and the Company’s $2.5 million inventory stocking order from WEP in the first quarter.
As of June 30, 2023, Y-mAbs has
delivered DANYELZA to 56 centers across the U.S., a sequential increase of 6% in the number of centers since the first quarter of 2023.
During the second quarter of 2023, approximately 61% of the vials sold in the U.S. were sold outside of Memorial Sloan Kettering Cancer
Center (“MSKCC”), which is in line with the first quarter of 2023.
Operating Expenses
Cost of Goods Sold
Cost of goods sold was $4.6 million
and $1.1 million for the three months ended June 30, 2023 and 2022, respectively. The increased cost of goods sold was driven by
increased product revenue in the three months ended June 30, 2023 and an inventory write-down of $0.5 million in the three months
ended June 30, 2023. Cost of goods sold was $6.7 million and $3.0 million for the six months ended June 30, 2023 and 2022,
respectively. The increase in cost of goods sold was primarily driven by increased product revenue.
The Company’s gross margin decreased
in the three and six months ended June 30, 2023, compared to the same periods in 2022, as a result of increased revenues from geographic
areas outside of the United States, which were at a lower gross margin. The Company’s cost of goods sold includes amounts related
to materials, third-party contract manufacturing, third-party packaging services, freight, labor costs for personnel involved in the
manufacturing process, third-party royalties for approved products, and indirect overhead costs.
Research and Development
Research and development expenses were
$12.1 million for the three months ended June 30, 2023, a reduction of 54% compared
to $26.4 million for the three months ended June 30, 2022. The $14.3 million decrease
was primarily due to decreased spending on deprioritized programs in connection with the Company’s previously announced restructuring
plan, resulting in a $6.6 million decrease related to outsourced manufacturing, a $3.2
million decrease in personnel-related costs, and a $2.5 million decrease in outsourced
research and supplies.
For the six months ended June 30,
2023, research and development expenses were $25.5 million, a reduction of 48% compared
to $49.3 million for the six months ended June 30, 2022. The $23.8 million decrease
was primarily due to decreased spending on deprioritized programs as described above, resulting in a $12.3
million decrease related to outsourced manufacturing, a $4.8 million decrease in
outsourced research and supplies, a $2.9 million decrease in clinical trials and a $2.1
million decrease in personnel-related costs.
Y-mAbs recorded a restructuring charge
of $3.4 million in research and development expenses during the six months ended June 30,
2023, in connection with the restructuring plan.
Selling, General, and Administration
Selling, general, and administrative
expenses were $11.3 million for the three months ended June 30, 2023, a reduction of
51.1% compared to $23.1 million for the three months ended June 30, 2022. The $11.8 million
decrease in selling, general and administrative expenses was primarily attributable to a $10.9 million charge related to contractual
severance related benefits for the Company’s former Chief Executive Officer in connection with his departure in the second quarter
of 2022.
For the six months ended June 30,
2023, selling, general, and administrative expenses were $23.5 million, a reduction of 35.6%
compared to $36.5 million for the six months ended June 30, 2022. The $13.0 million decrease in SG&A expenses was primarily
attributable to the contractual severance-related benefits described above.
Y-mAbs recorded a restructuring charge
of $1.1 million in selling, general, and administrative expenses during the six months ended June 30, 2023, in connection with the
restructuring plan.
Net Loss
Y-mAbs reported a net loss for the second
quarter ended June 30, 2023, of $6.3 million, or ($0.14)
per basic and diluted share, compared to a net loss of $41.1 million, or ($0.94)
per basic and diluted share, for the quarter ended June 30, 2022. For the six months ended June 30, 2023, the Company
reported a net loss of $12.7 million, or $0.29 per
basic and diluted share, compared to a net loss of $69.2 million, or $1.58 per basic and diluted share, for the six months ended June 30,
2022. The favorable decrease in net loss was primarily driven by an increase in DANYELZA U.S. product revenues in the second quarter
and six months ended June 30, 2023, an incremental benefit from expanding into international markets, decreased research and development
cost, and decreased selling, general and administration cost, partially offset by the unfavorable impact of restructuring charges, all
as noted above.
Cash and Cash Equivalents
As of June 30, 2023, Y-mAbs had
approximately $87.9 million in cash and cash equivalents which, together with anticipated DANYELZA product revenues, is expected to support
operations as currently planned into 2026. This estimate reflects the Company’s current business plan that is supported by assumptions
that may prove to be inaccurate, such that Y-mAbs could use its available capital resources sooner than it currently expects.
Financial Guidance
Management reiterates its full year
2023 financial guidance, as updated on May 8, 2023:
| · | Anticipated
DANYELZA® net product revenues expected to be between
$80 million and $85 million; |
| · | Anticipated
operating expenses expected to be between $115 million and $120 million; |
| · | Anticipated
total annual cash burn expected to be between $40 million and $50 million; and |
| · | Cash
and cash equivalents anticipated to support operations as currently planned into 2026. |
Webcast and Conference Call
Y-mAbs will host a conference call on
Friday, August 11, 2023, at 9:00 a.m. EDT. To participate in the call, please use the following dial-in information.
Investors (domestic): |
877-407-0792 |
Investors (international): |
201-689-8263 |
Conference ID: |
13739908 |
To
access a live webcast of the update, please use this link.
About Y-mAbs
Y-mAbs
is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic
cancer products. In addition to conventional antibodies, the Company’s technologies include bispecific antibodies generated using
the Y-BiClone platform and the SADA platform. The Company’s broad and advanced product pipeline includes one FDA-approved product,
DANYELZA® (naxitamab-gqgk), which targets tumors that express GD2, and one product candidate at the registration stage, OMBLASTYS®
(omburtamab), which targets tumors that express B7-H3.
Forward-Looking
Statements
Statements in this
press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical
facts, may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, statements about our business
model, including financial outlook for 2023 and beyond, including estimated operating expenses, total cash burn and DANYELZA product
revenue and sufficiency of cash resources and related assumptions; the restructuring, including the reduction in workforce and revised
business plan, and the expected impacts, expenses and benefits thereof, including potential cost-savings from the reduction in force,
expected reduction of operating expenses and any expectations with respect to cost savings to be derived therefrom; implied and express
statements regarding the future of the Company’s business, including with respect to expansion and its goals; the Company’s
plans and strategies, development, commercialization and product distribution plans, including potential partnerships; expectations with
respect to omburtamab; expectations with respect to our products and product candidates, including potential territory and label expansion
of DANYELZA and the potential market opportunity related thereto and potential benefits thereof, and the potential of the SADA Technology,
including the development of the first tumor binding dataset, and potential benefits and applications thereof; expectations relating
to key anticipated development milestones, including potential expansion of international commercialization efforts with respect to DANYELZA
development efforts and the SADA Technology, including potential indications and applications, and the timing thereof; expectations with
respect to current and future clinical and pre-clinical studies and our research and development programs, including with respect to
timing and results; expectations related to the timing of the initiation and completion of regulatory submissions; regulatory, marketing
and reimbursement approvals; including satisfaction of conditions to approvals; additional product candidates and technologies; expectations
regarding collaborations or strategic partnerships and the potential benefits thereof; expectations related to the use of cash and cash
equivalents, and the need for, timing and amount of any future financing transaction; expectations with respect to the Company’s
future financial performance; and other statements that are not historical facts. Words such as ‘‘anticipate,’’
‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’
‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’
‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’
‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will”, ‘‘would’’,
“guidance,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking
statements contain these identifying words. Our product candidates and related technologies are novel approaches to cancer treatment
that present significant challenges. Actual results may differ materially from those indicated by such forward-looking statements as
a result of various factors, including but not limited to: risks associated with our financial condition and need for additional capital;
the risks that actual results of our restructuring plan and revised business plan will not be as expected; risks associated with our
development work; cost and success of our product development activities and clinical trials; the risks of delay in the timing of our
regulatory submissions or failure to receive approval of our drug candidates; the risks related to commercializing any approved pharmaceutical
product including the rate and degree of market acceptance of our product candidates; development of our sales and marketing capabilities
and risks associated with failure to obtain sufficient reimbursement for our products; the risks related to our dependence on third parties
including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; the risks related to government
regulation; risks related to market approval, risks associated with protection of our intellectual property rights; risks related to
employee matters and managing growth; risks related to our common stock, risks associated with macroeconomic conditions, including the
conflict between Russia and Ukraine and sanctions related thereto, inflation, increased interest rates, uncertain global credit and capital
markets and disruptions in banking systems; and other risks and uncertainties affecting the Company including those described in the
"Risk Factors" section included in the Company’s Annual Report on Form 10-K for the fiscal year ending December 31,
2022, the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 and future filings and reports
by the Company including the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023. Any forward-looking
statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking
statement, whether as a result of new information, future events or otherwise.
DANYELZA®,
OMBLASTYS® and Y-mAbs® are registered trademarks of Y-mAbs Therapeutics, Inc.
Investor Contact:
Courtney Dugan
VP, Head of Investor Relations
cdu@ymabs.com
Y-MABS THERAPEUTICS, INC. |
Consolidated Balance Sheets |
(unaudited) |
(In thousands, except share and per share data) |
| |
| | |
| |
| |
June 30, | | |
December 31, | |
| |
2023 | | |
2022 | |
ASSETS | |
| | | |
| | |
CURRENT ASSETS | |
| | | |
| | |
Cash and cash equivalents | |
$ | 87,909 | | |
$ | 105,762 | |
Accounts receivable, net | |
| 19,118 | | |
| 12,531 | |
Inventories | |
| 5,187 | | |
| 6,702 | |
Other current assets | |
| 3,570 | | |
| 5,452 | |
Total current assets | |
| 115,784 | | |
| 130,447 | |
Property and equipment, net | |
| 375 | | |
| 604 | |
Operating lease right-of-use assets | |
| 1,178 | | |
| 1,739 | |
Intangible assets, net | |
| 2,809 | | |
| 2,986 | |
Other assets | |
| 12,250 | | |
| 5,680 | |
TOTAL ASSETS | |
$ | 132,396 | | |
$ | 141,456 | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | |
| | | |
| | |
LIABILITIES | |
| | | |
| | |
Accounts payable | |
$ | 7,252 | | |
$ | 14,175 | |
Accrued liabilities | |
| 16,152 | | |
| 13,241 | |
Operating lease liabilities, current portion | |
| 829 | | |
| 868 | |
Total current liabilities | |
| 24,233 | | |
| 28,284 | |
Accrued milestones and royalty payments | |
| 2,250 | | |
| 2,250 | |
Operating lease liabilities, long-term portion | |
| 416 | | |
| 899 | |
Other liabilities | |
| 816 | | |
| 802 | |
TOTAL LIABILITIES | |
| 27,715 | | |
| 32,235 | |
| |
| | | |
| | |
STOCKHOLDERS’ EQUITY | |
| | | |
| | |
Preferred stock, $0.0001 par value, 5,500,000 shares authorized and none issued at June 30, 2023 and December 31, 2022 | |
| - | | |
| - | |
Common stock, $0.0001 par value, 100,000,000 shares authorized at June 30, 2023 and December 31, 2022; 43,620,192 and 43,670,109 shares issued at June 30, 2023 and December 31, 2022, respectively | |
| 4 | | |
| 4 | |
Additional paid-in capital | |
| 552,369 | | |
| 543,929 | |
Accumulated other comprehensive income | |
| 1,043 | | |
| 1,331 | |
Accumulated deficit | |
| (448,735 | ) | |
| (436,043 | ) |
TOTAL STOCKHOLDERS’ EQUITY | |
| 104,681 | | |
| 109,221 | |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | |
$ | 132,396 | | |
$ | 141,456 | |
Y-MABS THERAPEUTICS, INC. |
Consolidated Statements of Net Loss and Comprehensive Loss |
(unaudited) |
(In thousands, except share and per share data) |
| |
| | |
| | |
| | |
| |
| |
Three months ended June 30, | | |
Six months ended June 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
REVENUES | |
| | | |
| | | |
| | | |
| | |
Product revenue, net | |
$ | 20,751 | | |
$ | 9,797 | | |
$ | 41,002 | | |
$ | 20,283 | |
License revenue | |
| — | | |
| 1,000 | | |
| — | | |
| 1,000 | |
Total revenues | |
| 20,751 | | |
| 10,797 | | |
| 41,002 | | |
| 21,283 | |
OPERATING COSTS AND EXPENSES | |
| | | |
| | | |
| | | |
| | |
Cost of goods sold | |
| 4,649 | | |
| 1,140 | | |
| 6,732 | | |
| 2,972 | |
License royalties | |
| — | | |
| 100 | | |
| — | | |
| 100 | |
Research and development | |
| 12,055 | | |
| 26,420 | | |
| 25,473 | | |
| 49,332 | |
Selling, general, and administrative | |
| 11,270 | | |
| 23,082 | | |
| 23,521 | | |
| 36,520 | |
Total operating costs and expenses | |
| 27,974 | | |
| 50,742 | | |
| 55,726 | | |
| 88,924 | |
Loss from operations | |
| (7,223 | ) | |
| (39,945 | ) | |
| (14,724 | ) | |
| (67,641 | ) |
OTHER INCOME/(LOSS), NET | |
| | | |
| | | |
| | | |
| | |
Interest and other income/(loss) | |
| 1,100 | | |
| (1,186 | ) | |
| 2,211 | | |
| (1,558 | ) |
LOSS BEFORE INCOME TAXES | |
| (6,123 | ) | |
| (41,131 | ) | |
| (12,513 | ) | |
| (69,199 | ) |
Provision for income taxes | |
| 179 | | |
| — | | |
| 179 | | |
| — | |
NET LOSS | |
$ | (6,302 | ) | |
$ | (41,131 | ) | |
$ | (12,692 | ) | |
$ | (69,199 | ) |
Other comprehensive income/(loss) | |
| | | |
| | | |
| | | |
| | |
Foreign currency translation | |
| 18 | | |
| 1,422 | | |
| (288 | ) | |
| 1,733 | |
COMPREHENSIVE LOSS | |
$ | (6,284 | ) | |
$ | (39,709 | ) | |
$ | (12,980 | ) | |
$ | (67,466 | ) |
Net loss per share attributable to common stockholders, basic and diluted | |
$ | (0.14 | ) | |
$ | (0.94 | ) | |
$ | (0.29 | ) | |
$ | (1.58 | ) |
Weighted average common shares outstanding, basic and diluted | |
| 43,663,112 | | |
| 43,718,748 | | |
| 43,667,385 | | |
| 43,713,967 | |
v3.23.2
Cover
|
Aug. 10, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Aug. 10, 2023
|
Entity File Number |
001-38650
|
Entity Registrant Name |
Y-MABS THERAPEUTICS, INC.
|
Entity Central Index Key |
0001722964
|
Entity Tax Identification Number |
47-4619612
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
230 Park Avenue
|
Entity Address, Address Line Two |
Suite 3350
|
Entity Address, City or Town |
New York
|
Entity Address, State or Province |
NY
|
Entity Address, Postal Zip Code |
10169
|
City Area Code |
646
|
Local Phone Number |
885-8505
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, $0.0001 par value
|
Trading Symbol |
YMAB
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Jul 2023 to Jul 2024